1910 Genetics utilizes a multimodal AI platform that integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to enhance drug discovery for small and large molecules. The company focuses on delivering novel drug candidates for neurological, autoimmune diseases, and cancer while providing software solutions to pharmaceutical and technology partners.
Funding
$25.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Drug discovery is a complex and time-consuming process, often hindered by the limitations of traditional methods in effectively integrating diverse data types and predicting drug efficacy. Existing approaches struggle to efficiently identify promising drug candidates for complex diseases like neurological disorders, autoimmune conditions, and cancer.
Solution
1910 Genetics offers a multimodal AI platform designed to accelerate and enhance drug discovery for both small and large molecules. The platform uniquely integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to improve the accuracy and efficiency of identifying novel drug candidates. By combining these data streams with laboratory automation, the platform aims to deliver promising therapeutic options and software solutions to pharmaceutical and technology partners. This integrated approach enables the company to advance its internal pipeline, focusing on developing treatments for neurological, autoimmune diseases, and cancer.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions seeking to leverage AI and automation to improve their drug discovery processes.
Features
- Multimodal AI platform integrating computational, wet lab proxy, and wet lab ground truth biological data
- Laboratory automation for efficient data generation and validation
- CANDID-CNS™ AI model for blood-brain barrier permeability prediction
- Capabilities for both small and large molecule drug discovery
- Internal pipeline focused on neurological, autoimmune diseases, and cancer